Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908947 · ClinicalTrials.gov registry record · NA
CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")
A NA study, sponsored by C. R. Bard.
- Terminated
- Registry status
- NA
- Development phase
- 173
- Enrollment target
NCT00908947 is a NA study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 173 participants.
The verdict
NCT00908947, a NA study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- NA
- Development phase
- 173 participants
- Enrollment target
Study Summary
The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System").
Interventions
- DEVICE PTA followed by placement of LifeStent® Vascular Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2011-02 |
| Est. Completion | 2018-09-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908947
The ClinicalTrials.gov registry entry for NCT00908947 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTA followed by placement of LifeStent® Vascular Stent is the first listed.
NCT00908947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908947 about?
NCT00908947 is a clinical study titled "CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")". The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System").
What is the current status of trial NCT00908947?
This trial is currently terminated. It is a NA study. The enrollment target is 173 participants. The study started on 2011-02. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT00908947?
The interventions under investigation include: PTA followed by placement of LifeStent® Vascular Stent (DEVICE).
Who is sponsoring clinical trial NCT00908947?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.